Project: Comprehensive in vitro immune response testing
COMPIT aims to position itself in the (bio)pharmaceutical market with the development of a unique in vitro platform for the testing and prediction of the full human immune response to drugs. The system merges cutting-edge immune response testing, 3D tissue models and ultrasensitive analytical assays based on the contemporary theory of the ‘Danger Model’. COMPIT is outperforming current immune response testing and is complementary to current information obtained from preclinical studies.
Acronym | COMPIT (Reference Number: 10456) |
Duration | 01/08/2016 - 01/08/2018 |
Project Topic | Biological Sciences / Technologies |
Network | Eurostars 2 |
Call | Eurostars Cut-Off 5 |